All Updates

As Governor Daniel McKee prepares for his State of the State address, patient advocates are highlighting the results of a new report by the American Cancer Society Cancer Action Network (ACS CAN), which found that over 70% of commercially-insured patients encountered out-of-pocket expenses for follow-up breast cancer diagnostic tests in 2023. These follow-up tests, such as a diagnostic mammogram, MRI, ultrasound or biopsy, are medically recommended next steps to determine if an individual may or may not have cancer; however, barriers like cost can keep people from getting them.

Last Friday , the U.S. Supreme Court announced its decision to grant the government’s petition for certiorari in the Braidwood Management v. Becerra case. At the core of this case is the requirement under the Affordable Care Act (ACA) for most insurers to cover preventive services recommended by the

COLUMBIA, S.C. – As the 2025 legislative session begins Tuesday, the American Cancer Society Cancer Action Network (ACS CAN) urges lawmakers to support policies that will reduce the cancer burden in the Palmetto State. ACS CAN South Carolina Government Relations Director Beth Johnson released the following statement: “We

A new report by the American Cancer Society Cancer Action Network (ACS CAN) found that over 70% of commercially-insured patients encountered out-of-pocket expenses for follow-up breast cancer diagnostic tests in 2023.

A new report by the American Cancer Society Cancer Action Network (ACS CAN) found that over 70% of commercially-insured patients encountered out-of-pocket expenses for follow-up breast cancer diagnostic tests in 2023.

A new report by the American Cancer Society Cancer Action Network (ACS CAN) found that over 70% of commercially-insured patients encountered out-of-pocket expenses for follow-up breast cancer diagnostic tests in 2023. These follow-up tests, such as a diagnostic mammogram, MRI, ultrasound or biopsy, are medically recommended next steps to determine if an individual may or may not have cancer; however, barriers like cost can keep people from getting them.

OLYMPIA, Wash. -- As Washington legislators convene today for a new session, American Cancer Society Cancer Action Network advocates will ask them to prioritize patients' ready access to needed and proven biomarker testing. Biomarker testing is about identifying the most effective treatment for patients with cancer and other serious illnesses.

A new report by the American Cancer Society Cancer Action Network (ACS CAN) found that over 70% of commercially-insured patients encountered out-of-pocket expenses for follow-up breast cancer diagnostic tests in 2023. These follow-up tests, such as a diagnostic mammogram, MRI, ultrasound or biopsy, are medically recommended next steps to determine if an individual may or may not have cancer; however, barriers like cost can keep people from getting them.

Last Friday , the U.S. Supreme Court announced its decision to grant the government’s petition for certiorari in the Braidwood Management v. Becerra case. At the core of this case is the requirement under the Affordable Care Act (ACA) for most insurers to cover preventive services recommended by the